ALKERMES | ALKS - Creditori Commerciali





Creditori Commerciali Cambiamento Data
AbbVie USD 3.59B 28.65B 2025-12
Acadia Pharmaceuticals USD 44.57M 32.32M 2026-06
ALKERMES USD 142.86M 40.5M 2026-06
Amgen USD 2.86B 16.65B 2026-06
Biogen USD 403.9M 45.4M 2026-06
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Bristol-Myers Squibb USD 4.16B 76M 2026-06
Coherus Biosciences USD 9.91M 14.98M 2025-12
Eli Lilly USD 5.03B 350M 2026-03
Gilead Sciences USD 645M 70M 2026-03
Heron Therapeutics USD 8.97M 24K 2026-03
Ionis Pharmaceuticals USD 47.7M 21.67M 2026-06
J&J USD 9.22B 1.24B 2026-06
Malin Corporation EUR 700K 200K 2024-12
Merck USD 3.86B 541M 2026-03
Minerva Neurosciences USD 640K 305K 2025-12
Nektar Therapeutics USD 10.03M 744K 2026-03
Neurocrine Biosciences USD 691.3M 145.8M 2026-03
Otsuka Holdings JPY 216.64B 20.6B 2026-06
Ovoca Bio EUR 1.3M 1.11M 2025-12
Pfizer USD 4.58B 75M 2026-06
Regeneron Pharmaceuticals USD 1.16B 132.2M 2026-06
Vertex Pharmaceuticals USD 3.61B 135M 2026-06